MD Anderson
The research team developed a DNA methylation-based classifier to distinguish between small cell lung cancer subtypes.
Written by early OGM adopters, the framework describes best practices for the technology's clinical implementation for hematological malignancies.
VolitionRx, MD Anderson Cancer Center Partner to Study Cancer Patients With Sepsis
The study will use Volition's CE-marked Nu.Q NETs test to evaluate the role of neutrophil extracellular traps in cancer patients with sepsis.
MD Anderson, BostonGene Ink Collaboration to Develop Cancer Diagnostics
The partners will validate therapeutically actionable cancer biomarker targets and develop multiple tests from this research.
Nucleix, MD Anderson Partner on Methylation-Based Lung Cancer Dx Tests
The collaborators will initially evaluate methylation markers that they believe are important for characterizing lung cancer subtypes.
Nov 10, 2016